On September 10, 2026 Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, reported that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit’s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x’s oncology-focused clinical research studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
10x Genomics is a leader in single cell and spatial biology, with its technologies cited in more than 10,000 research publications and enabling discoveries across oncology, immunology, neuroscience and other fields.
The work brings together molecular insights generated using 10x’s Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analyzing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to the underlying biology of tumors and identify biomarkers associated with treatment response and resistance.
"10x Genomics has built powerful tools for understanding the molecular organization of tissue," said Brandon Suh, CEO of Lunit. "Lunit SCOPE IO adds the ability to analyze the full H&E landscape at scale. Together, we believe these technologies can help researchers connect deep molecular insight with the tissue patterns that pathologists recognize every day."
"Spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment," said Roman Yelensky, Vice President, Clinical Applications of 10x Genomics. "By combining that molecular depth with Lunit’s AI-based analysis of the same H&E images pathologists work with every day, we can give researchers a more complete view of the tumor to accelerate the discovery of biomarkers that could inform treatment strategies and enable potential future diagnostic development."
The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x’s broader effort to explore potential future diagnostic applications of spatial technologies in oncology.
Lunit SCOPE IO uses deep learning to analyze whole-slide H&E pathology images and characterize tissue features including tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other features of the tumor microenvironment. Used alongside 10x’s spatial technologies, these analyses provide additional tissue context that complements molecular profiling in oncology clinical research.
(Press release, Lunit, SEP 10, 2026, View Source [SID1234670736])